Replies to post #590272 on NorthWest Biotherapeutics Inc (NWBO)

[hoffmann6383]

great info here. thanks atl.

[ccie1024]

Ashkan describes differentiation in the trial as using IL-4 and GM-CSF. Can the maturation agent be replaced like that simply because it’s in a patent?

Still finding this hard to believe.

Would that not be like saying when L is approved it will be for clean room production (as in the trial) and for Flaskworks.

[CaptainObvious]

That's impressive

[branster]

ATLnsider, does adding the activation agent poly-ICLC to DCVax-L have any downside as far adverse events since we know that DCVax has very little or no side effects as a cancer treatment which puts NWBIO as a leader in that aspect.

[newman2021]

Beautiful explanation! Thanks ATL for making us understanding what constitutes a DcVaxL vaccine. Crystal clear now.